Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 87

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 87
---
 with the SKNJCT-003 study and trials.

The principal risks related to the Company's future performance are that the trials are unsuccessful, the Company does not receive FDA approval to proceed with the next stage of its research and development, may be placed on clinical hold by the FDA, or the Company is unsuccessful in obtaining future funding needed to continue its research and development. These are customary risks for a development stage pharmaceutical Company and are less acute than for a Company with a less advanced product. Nevertheless, there can be no assurance that the Company will be able to complete its clinical trials, that the trials will be successful, or that the product will ultimately reach commercialization.

Other income (expense):

Interest income, net, was $40,004 and $63,870 for the three and six months ending June 30, 2025, respectively. Interest income for the three and six months ended June 30, 2025 relates to interest income earned on short-term money market investments. Interest expense, net was $79,025 for the three and six months ending June 30, 2024, related to interest on convertible note payables.

Change in fair value of Debentures was $200,000 for both the three and six months ending June 30, 2025. The $200,000 relates to the remeasurement of the Debentures at fair value at the reporting date.

The following table outlines our statements of loss and comprehensive loss for the years ended December 31, 2024 and 2023:

|                                               |     | Years ended December 31, |   |     |            |   |     |            |   |
|                                               |     |                     2024 
                        $ |   |     |       2023 
          $ |   |     |     Change |   |
| General and administrative                    |     |                7,653,116 |   |     |  4,536,367 |   |     |  3,116,749 |   |
| Research and development                      |     |                3,527,786 |   |     |    193,578 |   |     |  3,334,208 |   |
| Total operating expenses                      |     |               11,180,902 |   |     |  4,729,945 |   |     |  6,450,957 |   |
| Loss from operations                          |     |              (11,180,902 |